The Clinical Imaging Strategy That Safeguards Your Trial's Ocular Endpoints

In GLP1 and neurology trials, the smallest imaging misstep can compromise entire studies. With endpoints tied to ocular health—such as diabetic retinopathy risk in GLP1 programs or optic nerve changes in neurology trials—precision imaging has become non-negotiable. These studies depend on detecting subtle retinal or neuro-ophthalmic changes early, yet imaging variability, equipment gaps, and delayed reviews often trigger costly delays, protocol amendments, and unreliable data.

The evolving clinical landscape demands imaging strategies that are standardized, scalable, and proactive. In neurology, technologies such as OCT and fundus photography help track retinal biomarkers linked to cognitive decline and disease progression. Bridging the gap from preclinical insights to clinical protocols requires foresight, as animal models rarely capture the nuanced functional outcomes regulators expect. By planning imaging strategy upfront—vetting protocols, validating feasibility, and aligning timelines—sponsors can de-risk studies, accelerate enrollment, and protect critical endpoints. Ultimately, imaging is not just a diagnostic tool but a trial-shaping strategy. Strong imaging execution delivers cleaner data, faster decisions, and greater regulatory confidence—making it the foundation of modern GLP1 and neurology development.